Key result
ALL survivors have ~100% higher metabolic syndrome prevalence than controls, driven by total body irradiation.
Why the study?
Metabolic syndrome is a risk factor for early cardiovascular morbidity and mortality that affects up to 34% of childhood acute lymphoblastic leukemia survivors.
Cross-Sectional (n=734)
Yes
Childhood ALL survivors, particularly those treated with total body irradiation, have a significantly increased risk of metabolic syndrome and insulin resistance compared to healthy controls.
Answers are grounded in this paper and cite their sources.
Supports MetS screening in ALL survivors post-TBI; leaves open whether intervention improves outcomes.
BACKGROUND: Metabolic syndrome (MetS), a risk factor for early cardiovascular morbidity and mortality, is seen in up to 34% of survivors of childhood acute lymphoblastic leukemia (ALL). PROCEDURE: We performed a Danish, national cross-sectional study of ALL survivors (aged 1-45 years at diagnosis) treated according to the NOPHO ALL2008 protocol, examined at least 1 year after treatment cessation. The study included non-cancer community controls, matched on sex and age. We explored the prevalence and components of the MetS criteria (hyperglycemia, hypertension, increased waist circumference (WC), and dyslipidemia) and glucose homeostasis (insulin and C-peptide). RESULTS: We included 366 survivors of ALL (participation rate 84%) and 368 controls. Median age (IQR) at follow-up examination was 14.1 (10.8-21.8) years, and follow-up time after the ALL diagnosis was 6.9 (4.7-9.1). The prevalence of MetS in survivors was 7.6% and in controls 3.8 % (p = 0.039). The increased MetS prevalence was driven by ALL patients undergoing total body irradiation (TBI), and age and body mass index (BMI) percentile ≥95 at diagnosis (p ≤ 0.01). The MetS prevalence in non-TBI patients did not differ from controls (p = 0.43), but non-TBI patients more often fulfilled the MetS criteria WC and/or elevated high-density lipoprotein (p < 0.03). Survivors had higher serum insulin and C-peptide than controls (p < 0.01). CONCLUSIONS: ALL survivors have an increased risk of MetS compared with controls, essentially driven by the patients treated with TBI. The MetS frequency in non-TBI patients is equal to controls, but non-TBI patients more often have one or two components of Mets. ALL survivors seem slightly more insulin-resistant than controls.
No takes yet. Share an insight, caveat, or question.
Skipper et al. (2025) conducted a cross-sectional in Acute Lymphoblastic Leukemia survivors (n=734). ALL survivorship vs. Non-cancer community controls was evaluated on Prevalence of Metabolic Syndrome (MetS) (p=0.039). ALL survivors had a higher prevalence of metabolic syndrome compared to matched community controls, driven primarily by patients who received total body irradiation.
Synapse has enriched 10 related papers. Consider them for comparative context: